Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab in Migraine Patients With Prior Inadequate Response to CGRP Therapies
NCT06701526Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of eptinezumab in migraine, sponsored by Lundbeck. Started Dec 2024; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06701526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701526.